Overview
Benign mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by chronic inflammation and blistering primarily affecting mucous membranes such as the oral cavity, eyes, nose, pharynx, larynx, trachea, esophagus, genital, and perianal regions 13.Diagnosis
Clinical Presentation: Predominant mucosal lesions including gingival erythema, oral lesions, conjunctival scarring, and potential airway obstruction 13.
Direct Immunofluorescence: Essential for detecting tissue-bound IgG, IgA, and/or complement C3 12.
Serological Testing: Indirect immunofluorescence assays and ELISA for circulating autoantibodies targeting BP180, BP230, laminin 332, and type VII collagen 23.
Autoantibody Levels: Often present in low levels and vary by clinical site 2.Management
First-Line Treatments:
- Corticosteroids: Typically initiated with systemic corticosteroids (dose varies; consult specific guidelines) 1.
- Immunosuppressants: Addition of second-line agents like azathioprine, mycophenolate mofetil, or ciclosporin for refractory cases 1.
Adjunctive Treatments:
- Topical Therapy: Topical corticosteroids for localized lesions 1.
- Biologic Agents: Rituximab considered in severe refractory cases 1.Special Populations
Pregnancy: Specific management strategies not detailed in provided abstracts 123.
Pediatrics: Limited evidence; management parallels adult cases with caution 13.
Elderly: Consideration of comorbidities and potential drug interactions crucial 1.
Comorbidities: Management tailored to coexisting conditions, emphasizing interdisciplinary cooperation 1.Key Recommendations
Diagnosis Requires Direct Immunofluorescence and Serological Testing: Essential for confirming MMP diagnosis (Evidence: Strong 12).
Systemic Corticosteroids as Initial Treatment: Recommended for managing MMP due to its broad efficacy (Evidence: Moderate 1).
Consider Immunosuppressive Agents for Refractory Cases: Adjunctive use of agents like azathioprine or mycophenolate mofetil is advised (Evidence: Moderate 1).
Interdisciplinary Approach Essential: Given the multisite involvement, collaboration across specialties is crucial (Evidence: Expert opinion 1).References
1 Hofmann SC, Günther C, Böckle BC, Didona D, Ehrchen J, Gaskins M et al.. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022. link
2 Schmidt E, Rashid H, Marzano AV, Lamberts A, Di Zenzo G, Diercks GFH et al.. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. Journal of the European Academy of Dermatology and Venereology : JEADV 2021. link
3 Rashid H, Lamberts A, Borradori L, Alberti-Violetti S, Barry RJ, Caproni M et al.. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. Journal of the European Academy of Dermatology and Venereology : JEADV 2021. link